| PRECLINICAL | evidence | Changes in Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Exposures Following Recent Demand for Weight Management: A Retrospective Review of California Poison Control System Data. | Wegovy | — | 2025-08-01 |
| PRECLINICAL | evidence | Are Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review. | Ozempic | — | 2025-08-01 |
| PRECLINICAL | evidence | Evaluation of Pre-Treatment Assessment of Semaglutide Users: Balancing the Benefits of Weight Loss vs. Potential Health Consequences. | Ozempic | — | 2025-07-26 |
| PRECLINICAL | evidence | "Ozempic Face": An Emerging Drug-Related Aesthetic Concern and Its Treatment with Endotissutal Bipolar Radiofrequency (RF)-Our Experience. | Ozempic | — | 2025-07-25 |
| PRECLINICAL | evidence | Long-acting hydrogel-based depot formulations of tirzepatide and semaglutide for the management of type 2 diabetes and weight. | Ozempic | — | 2025-07-05 |
| PRECLINICAL | evidence | Animal models for development of anti-obesity drugs in the age of GLP-1 agents. | Ozempic | Weight & fat loss | 2025-07-01 |
| PRECLINICAL | evidence | FDA Accepts Application for Oral Version of Wegovy. | Wegovy | — | 2025-07-01 |
| PRECLINICAL | evidence | Effect of Ozempic on Diabetic Nephropathy: A Case Report. | Ozempic | — | 2025-07-01 |
| PRECLINICAL | evidence | Semaglutide in Heart Failure With Preserved Ejection Fraction: Emerging Evidence and Clinical Implications. | Ozempic | — | 2025-07-01 |
| PRECLINICAL | evidence | The Impact of Semaglutide on Metabolic Syndrome: A Case Report. | Ozempic | — | 2025-07-01 |
| PRECLINICAL | evidence | Otolaryngologic Side Effects of GLP-1 Receptor Agonists. | Ozempic | Glycemic control | 2025-07-01 |
| PRECLINICAL | evidence | GLP-1-based medications: Mechanisms involved in obesity treatment. | semaglutida | Weight & fat loss | 2025-07-01 |
| PRECLINICAL | evidence | Titration and discontinuation of semaglutide for weight management in commercially insured US adults. | Wegovy | Weight & fat loss | 2025-07-01 |
| PRECLINICAL | evidence | Medications for Weight Loss and MASLD: A National Survey of Hepatology and Gastroenterology Provider Practices, Attitudes, and Knowledge Before Resmetirom. | Ozempic | — | 2025-06-23 |
| PRECLINICAL | evidence | "I Believe in Santa Claus" and Ozempic: A Foucauldian Discourse Analysis of Holiday Health Advertising. | Ozempic | — | 2025-06-19 |
| PRECLINICAL | evidence | Reduced 90-Day Cardiovascular and Infectious Complications After Open Reduction Internal Fixation of Ankle Fractures in Type II Diabetic Patients Using Semaglutide Preoperatively. | Ozempic | Glycemic control | 2025-06-17 |
| PRECLINICAL | evidence | Real-world evaluation of the efficacy and safety of switching from weekly dulaglutide to weekly semaglutide: The SEMA-SWITCH study. | semaglutida | Glycemic control | 2025-06-01 |
| PRECLINICAL | evidence | Icodec: A Novel Once-Weekly Basal Insulin for Diabetes Management. | Ozempic | Glycemic control | 2025-06-01 |
| PRECLINICAL | evidence | Prognostic impact of glucagon-like peptide-1 receptor (GLP1R) expression on cancer survival and its implications for GLP-1R agonist therapy: an integrative analysis across multiple tumor types. | Ozempic | Glycemic control | 2025-06-01 |
| PRECLINICAL | evidence | Analyses of Off-Target Effects on Cardiac and Skeletal Muscles by Berberine, a Drug Used to Treat Cancers and Induce Weight Loss. | Ozempic | — | 2025-06-01 |
| PRECLINICAL | evidence | Semaglutide for cardiovascular risk reduction in people who are overweight or have obesity without diabetes (new indication). | Wegovy | — | 2025-06-01 |
| PRECLINICAL | evidence | Drugs for chronic heart failure. | Ozempic | — | 2025-05-26 |
| PRECLINICAL | evidence | Comment on "Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US". | Ozempic | — | 2025-05-01 |
| PRECLINICAL | evidence | Emergent role of Ozempic in treating women with PCOS related fertility issues. | Ozempic | — | 2025-05-01 |
| PRECLINICAL | evidence | Immunogenicity of Generic Peptide Impurities: Current Orthogonal Approaches. | Ozempic | — | 2025-05-01 |
| PRECLINICAL | evidence | Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy Risk Among Patients With Diabetes. | Ozempic | Glycemic control | 2025-05-01 |
| PRECLINICAL | evidence | Comparative Efficacy of Tirzepatide vs. Semaglutide in Reducing Body Weight in Humans: A Systematic Review and Meta-Analysis of Clinical Trials and Real-World Data. | Ozempic | — | 2025-05-01 |
| PRECLINICAL | evidence | Improved total shoulder arthroplasty outcomes associated with semaglutide utilization in patients with type II diabetes: a promising new addition to preoperative optimization. | Ozempic | — | 2025-05-01 |
| PRECLINICAL | evidence | Is global interest in fasting, intermittent fasting and the liver shifting? | Ozempic | — | 2025-04-27 |
| PRECLINICAL | evidence | A Closer Look at the Dermatological Profile of GLP-1 Agonists. | Ozempic | — | 2025-04-22 |
| PRECLINICAL | evidence | Online Information About Side Effects and Safety Concerns of Semaglutide: Mixed Methods Study of YouTube Videos. | Ozempic | Weight & fat loss | 2025-04-08 |
| PRECLINICAL | evidence | Effects of Semaglutide on Glycemic Control and Body Weight in Patients With Type 2 Diabetes: A Retrospective Cohort Study in a Primary Care Setting. | Ozempic | — | 2025-04-01 |
| PRECLINICAL | evidence | Consensus Statements on Managing Aesthetic Needs in Prescription Medication-Driven Weight Loss Patients: An International, Multidisciplinary Delphi Study. | Ozempic | Weight & fat loss | 2025-04-01 |
| PRECLINICAL | evidence | Survey among adult users of semaglutide for weight loss in Denmark: User characteristics, treatment expectations and experienced effects. | Wegovy | Weight & fat loss | 2025-04-01 |
| PRECLINICAL | evidence | Semaglutide 2.4 mg long-term clinical outcomes in patients with obesity or overweight: a real-world retrospective cohort study in the United States (SCOPE 12 months). | Wegovy | Weight & fat loss | 2025-04-01 |
| PRECLINICAL | evidence | From Prescription to Predicament: A Case of Semaglutide-Induced Discoid Lupus Erythematosus in an Adult Male Patient. | Ozempic | — | 2025-04-01 |
| PRECLINICAL | evidence | A renal indication for semaglutide (Ozempic). | Ozempic | — | 2025-03-03 |
| PRECLINICAL | evidence | Exploring Connections Between Weight-Loss Medications and Thyroid Cancer: A Look at the FDA Adverse Event Reporting System Database. | Ozempic | Weight & fat loss | 2025-03-01 |
| PRECLINICAL | evidence | Use of Semaglutide (Wegovy) in Adults in France: A Nationwide Drug Utilization Study. | Wegovy | Weight & fat loss | 2025-03-01 |
| PRECLINICAL | evidence | Clinical development of oral semaglutide for the treatment of type 2 diabetes mellitus: focusing on early phase clinical trials. | Rybelsus | — | 2025-03-01 |
| PRECLINICAL | evidence | Semaglutide, Popularly Known as Ozempic-What the Facial Plastic Surgeon Needs to Know. | Ozempic | — | 2025-03-01 |
| PRECLINICAL | evidence | Semaglutide utilization associated with reduced 90-day postoperative complications following single-level posterior lumbar fusion for patients with type II diabetes. | Ozempic | Glycemic control | 2025-03-01 |
| PRECLINICAL | evidence | CORRECTION: Ozempic v Mounjaro: what is the difference between semaglutide and tirzepatide? | Ozempic | — | 2025-02-07 |
| PRECLINICAL | evidence | Ozempic v Mounjaro: what is the difference between semaglutide and tirzepatide? | Ozempic | — | 2025-02-03 |
| PRECLINICAL | evidence | Lower Risk of Postoperative Complications and Rotator Cuff Retear Associated With Semaglutide Use in Patients with Type II Diabetes Mellitus Undergoing Arthroscopic Rotator Cuff Repair. | Ozempic | Glycemic control | 2025-02-01 |
| PRECLINICAL | evidence | A Hidden Tumor: Unraveling a Gastrointestinal Stromal Tumor in a 44-Year-Old Male Patient With Epigastric Pain. | Ozempic | — | 2025-02-01 |
| PRECLINICAL | evidence | The weight-loss drugs being tested in 2025: will they beat Ozempic? | Ozempic | — | 2025-02-01 |
| PRECLINICAL | evidence | Semaglutide-Associated Ischemic Colitis in a Patient Without Traditional Risk Factors: A Case Report. | Ozempic | — | 2025-02-01 |
| PRECLINICAL | evidence | Semaglutide-induced fixed drug eruption. | Ozempic | — | 2025-02-01 |
| PRECLINICAL | evidence | A systematic review of the use of GLP-1 receptor agonists in surgery. | Ozempic | Glycemic control | 2025-02-01 |